Key facts
- ReAlta Life Sciences’s last known valuation is $230.0M (Apr 2026).
- It has raised $155.4M across 5 recorded rounds; the latest was Early Stage VC ($25.0M) in Dec 2024.
- Notable investors include Virginia Innovation Partnership Corporation, Children's Research Holdings, Cock Island Capital, Cystic Fibrosis Foundation, Eriko Life Science Ventures — 12 tracked in total.
- ReAlta Life Sciences has filed 7 Form Ds with the SEC since 2018, most recently May 2025 ($12.0M sold to 85 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for ReAlta Life Sciences
Funding rounds
5 roundsAbout ReAlta Life Sciences
Developer of immunomodulatory therapeutics designed for the treatment of acute inflammatory and rare diseases. The company utilizes engineered peptides derived from a viral capsid protein to simultaneously inhibit early complement pathway activation and neutrophil-mediated inflammation, enabling healthcare professionals to address medical needs through beneficial inhibition of the complement system and inflammatory mechanisms.
- Sector
- Healthcare
- HQ
- Norfolk, VA, United States
- Employees
- 25
- Website
- realtalifesciences.com/
- Ownership
- Privately Held (backing)
ReAlta Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReAlta Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReAlta Life Sciences in its N-PORT filings yet. We sweep new filings monthly.